India’s Expanding Vaccines Market Offers Promise To Global And Local Drug Firms (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Several drug companies are gearing up to go full throttle into the Indian vaccines market with programs that go beyond pushing products and seek to build up public health awareness on a larger scale. GSK, Sanofi, Merck, Novartis and Pfizer are in the fray with local players Serum Institute of India, Bharat Biotech, and Panacea Biotec.
You may also be interested in...
Pressure For Bexsero: Fate Of Novartis Vaccines Unit Hangs On Success
The EU CHMP’s recommendation in favor of Novartis’ Meningitis B vaccine Bexsero is a positive turn for the company’s vaccines business, but with the division’s sales and profits languishing, some investors are wondering if Novartis should cut its losses and get out of the space.
WHO Delists Panacea Biotec's Combination Vaccines From Pre-qualified List; Move Comes A Year After Action Against Sanofi's Shantha Unit
MUMBAI - In a stern signal intended to ensure product quality, the World Health Organization delisted combination vaccines made by Indian vaccine maker Panacea Biotec Ltd. from its list of pre-qualified suppliers
Is Sanofi Planning High-Level Changes At India's Vaccines Unit Shantha? A Leading Biocon Scientist Joins Shantha
MUMBAI - Two years after it bagged Indian vaccines specialist Shantha Biotechnics Ltd. with an aim to develop low-cost vaccines, Sanofi is set to rollout significant changes in the management of its acquired Hyderabad site in Central India